Isolated case reports have described elevations in liver enzymes or rare instances of liver-related adverse events in patients taking semaglutide
While Semaglutide GLP-1 affects the portion of the brain responsible for monitoring and stabilizing blood sugar levels, it has also been found to have a profound effect on the regulation of hunger and fullness cues
Very common (10% of patients) Nausea peaks during titration, typically subsides within 48 weeks at a stable dose Vomiting, diarrhoea, constipation Abdominal pain or discomfort Reduced appetite (this is the therapeutic effect, not an adverse effect) Less common but serious stop and see a doctor Severe, persistent abdominal pain radiating to the back possible pancreatitis Right upper abdomen pain, fever, yellowing possible gallstones / gallbladder disease Persistent neck lump, hoarseness, difficulty swallowing evaluate thyroid Rapid heartbeat, severe dehydration from vomiting Hypoglycaemia when semaglutide is combined with insulin or sulfonylureas What the Indian data shows: a 2025 study of Indian patients found GI side effects are the leading cause of discontinuation, peaking during dose escalation
While it offers significant benefits, being aware of its side effects, including the possibility of developing a rash, is crucial for users
